SLC5A2 and type 2 diabetes mellitus: Therefore, the prescription rate of SGLT2 inhibitors had not been high [12], with dipeptidyl peptidase-4 (DPP-4) inhibitors most commonly used in real-world clinical practice for the treatment of Japanese patients with type 2 diabetes [13, 14] because of their safety and reliability in glycemic control among elderly patients and subjects with renal impairment [15, 16].